LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
TECX
Tectonic Therapeutic, Inc.
There isn't enough reported data to score TECX yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TECX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
TECX's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TECX PE Valuation
TECX has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
TECX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect TECX's earnings, revenue and profitability to hold roughly steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TECX on earnings quality, reporting a profit while its opponent remains loss making.
TECX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.63 | -$0.47 |
| Q2 2026 | -$4.57 | -$0.23 |
| Q1 2026 | -$4.46 | +$3.15 |
| Q4 2025 | -$4.05 | +$4.43 |
| Q3 2025 | -$4.16 | +$5.58 |
| Q2 2025 | -$4.34 | +$9.96 |
| Q1 2025 | -$7.61 | -192% |
| Q4 2024 | -$8.48 | -362% |
TECX is still losing money, but far less than before: $4.63 per share over the past year, against $39.72 at its worst in late 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
TECX Quarterly Revenue
TECX and LLY do not have enough comparable growth data to identify a winner.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over TECX on cash generation, producing positive trailing cash flow while its opponent burns cash.
TECX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$14.9M | +$3.1M |
| Q2 2026 | -$21.5M | -$6.8M |
| Q1 2026 | -$18.4M | -$5.3M |
| Q4 2025 | -$14.5M | +$2.4M |
| Q3 2025 | -$18M | +$1.8M |
| Q2 2025 | -$14.7M | +$367K |
| Q1 2025 | -$13.1M | -$5.5M |
| Q4 2024 | -$16.8M | -$8.8M |
TECX has burned cash in almost every quarter: −$69M over the past year, against −$63M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TECX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TECX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +740K shares |
| 1 year | +5.3% | +991K shares |
| 3 years | +434% | +16M shares |
| 5 years | +555% | +16.7M shares |
TECX has 20M diluted shares, up 5.3% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TECX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -3.3x | Net Cash |
| Q4 2023 | -9.1x | Net Cash |
TECX has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TECX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.0 | Neutral |
| Stochastic | 7.9 | Oversold |
TECX's weekly RSI is 39 (neutral) and its Stochastic is 8 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TECX PE vs Healthcare Sector
| Metric | TECX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TECX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TECX on trend strength, trading above more of its moving averages.
TECX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.5 | 2% below |
| 20 week MA | $28.1 | 25% below |
| 50 week MA | $27.0 | 22% below |
| 100 week MA | $25.8 | 19% below |
| 200 week MA | $22.3 | 5.7% below |
TECX is in a downtrend: it's below all five of its weekly moving averages, and 5.7% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TECX on returns for 2026, with the stronger performance.
TECX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $235.0 | $176.2 | -25% |
| 2021 | $176.2 | $46.9 | -73% |
| 2022 | $46.9 | $9.12 | -81% |
| 2023 | $9.12 | $16.3 | +79% |
| 2024 | $16.3 | $47.0 | +188% |
| 2025 | $47.0 | $20.9 | -56% |
| 2026 YTD | $20.9 | $21.0 | +0.8% |
TECX's yearly returns have swung widely, from +188% in 2024 to −81% in 2022. It's up 0.8% so far in 2026.